NO133802B - - Google Patents
Download PDFInfo
- Publication number
- NO133802B NO133802B NO343/71*[A NO34371A NO133802B NO 133802 B NO133802 B NO 133802B NO 34371 A NO34371 A NO 34371A NO 133802 B NO133802 B NO 133802B
- Authority
- NO
- Norway
- Prior art keywords
- vitamin
- acid
- group
- approx
- general formula
- Prior art date
Links
- 229930002330 retinoic acid Natural products 0.000 claims description 27
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- -1 n-decyl Chemical group 0.000 description 6
- 206010020915 Hypervitaminosis Diseases 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000006122 hypervitaminosis A Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- WKYDOCGICAMTKE-NBIQJRODSA-N n-ethyl retinamide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C WKYDOCGICAMTKE-NBIQJRODSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- AZJQQNWSSLCLJN-UHFFFAOYSA-N 2-ethoxyquinoline Chemical compound C1=CC=CC2=NC(OCC)=CC=C21 AZJQQNWSSLCLJN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH142870A CH529742A (de) | 1970-02-02 | 1970-02-02 | Verfahren zur Herstellung von Vitamin-A-Säureamiden |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO133802B true NO133802B (de) | 1976-03-22 |
| NO133802C NO133802C (de) | 1976-06-30 |
Family
ID=4210229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO343/71*[A NO133802C (de) | 1970-02-02 | 1971-02-01 |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS544948B1 (de) |
| AT (1) | AT303274B (de) |
| BE (1) | BE762345A (de) |
| CA (1) | CA963910A (de) |
| CH (1) | CH529742A (de) |
| DE (1) | DE2102586C2 (de) |
| DK (1) | DK136311B (de) |
| ES (1) | ES387834A1 (de) |
| FI (1) | FI52715C (de) |
| FR (1) | FR2081477B1 (de) |
| GB (1) | GB1283887A (de) |
| IE (1) | IE35133B1 (de) |
| IL (1) | IL35987A (de) |
| NL (1) | NL168415C (de) |
| NO (1) | NO133802C (de) |
| SE (1) | SE373133B (de) |
| YU (1) | YU34355B (de) |
| ZA (1) | ZA71142B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2300107C2 (de) * | 1973-01-03 | 1982-03-11 | Basf Ag, 6700 Ludwigshafen | Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen |
| US4310546A (en) * | 1978-07-31 | 1982-01-12 | Johnson & Johnson | Novel retinoids and their use in preventing carcinogenesis |
| DE2843915A1 (de) * | 1978-10-07 | 1980-04-24 | Basf Ag | N-benzoyl-retinylamine |
| DE2843870A1 (de) * | 1978-10-07 | 1980-04-24 | Basf Ag | N-hydroxypropylamide der all-e- und 13-z-retinsaeure |
| DE3002545A1 (de) * | 1980-01-25 | 1981-07-30 | Basf Ag, 6700 Ludwigshafen | 5-amino-tetrazol-derivate von retinsaeuren, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| CH651007A5 (de) * | 1982-06-24 | 1985-08-30 | Hoffmann La Roche | Polyenverbindungen. |
| KR100556682B1 (ko) * | 1995-09-01 | 2006-06-21 | 코스모페름 베.파우 | 스핑고이드염기의레티노일아미드계유도체 |
| US7566808B2 (en) | 2004-02-17 | 2009-07-28 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| JP2008515770A (ja) * | 2004-07-09 | 2008-05-15 | ディーエスエム アイピー アセッツ ビー．ブイ． | レチノイン酸のアミノ、アミノ酸またはペプチド結合体 |
| KR100837186B1 (ko) * | 2006-09-29 | 2008-06-13 | (주)아모레퍼시픽 | 항노화 효과를 나타내는 레티노익산 유도체 및 이의제조방법 |
| JP7178715B2 (ja) * | 2017-05-23 | 2022-11-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ジメチル－ノナテトラエニル－トリメチル－シクロヘキシル化合物およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH195065A (de) * | 1936-11-23 | 1938-01-15 | Int Suiker En Alcohol Compagni | Einrichtung an Vacuumapparaten zum Erleichtern des Auswechselns einzelner Röhren. |
| NL257621A (de) * | 1959-11-23 | |||
| FR1297730A (fr) * | 1960-11-04 | 1962-07-06 | Hoffmann La Roche | Préparation cosmétique |
| FR1320153A (fr) * | 1962-01-22 | 1963-03-08 | Sumitomo Chemical Co | Procédé de production de composés dérivés de l'acide de vitamine a 2-trans |
-
1970
- 1970-02-02 CH CH142870A patent/CH529742A/de not_active IP Right Cessation
- 1970-12-09 FI FI703317A patent/FI52715C/fi active
- 1970-12-15 NL NLAANVRAGE7018260,A patent/NL168415C/xx not_active IP Right Cessation
- 1970-12-28 YU YU3184/70A patent/YU34355B/xx unknown
-
1971
- 1971-01-11 ZA ZA710142A patent/ZA71142B/xx unknown
- 1971-01-12 IL IL35987A patent/IL35987A/xx unknown
- 1971-01-20 DE DE2102586A patent/DE2102586C2/de not_active Expired
- 1971-01-29 CA CA103,975A patent/CA963910A/en not_active Expired
- 1971-01-29 DK DK40571AA patent/DK136311B/da not_active Application Discontinuation
- 1971-01-29 FR FR7103020A patent/FR2081477B1/fr not_active Expired
- 1971-02-01 JP JP356271A patent/JPS544948B1/ja active Pending
- 1971-02-01 NO NO343/71*[A patent/NO133802C/no unknown
- 1971-02-01 ES ES387834A patent/ES387834A1/es not_active Expired
- 1971-02-01 BE BE762345A patent/BE762345A/xx not_active IP Right Cessation
- 1971-02-01 AT AT79971A patent/AT303274B/de not_active IP Right Cessation
- 1971-02-02 IE IE118/71A patent/IE35133B1/xx unknown
- 1971-02-02 SE SE7101274A patent/SE373133B/xx unknown
- 1971-04-19 GB GB20880/71A patent/GB1283887A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL35987A0 (en) | 1971-03-24 |
| ZA71142B (en) | 1971-10-27 |
| FR2081477B1 (de) | 1974-03-22 |
| IE35133L (en) | 1971-08-02 |
| FI52715B (de) | 1977-08-01 |
| GB1283887A (en) | 1972-08-02 |
| YU318470A (en) | 1978-12-31 |
| BE762345A (fr) | 1971-08-02 |
| NO133802C (de) | 1976-06-30 |
| NL168415B (nl) | 1981-11-16 |
| FR2081477A1 (de) | 1971-12-03 |
| JPS544948B1 (de) | 1979-03-12 |
| NL168415C (nl) | 1982-04-16 |
| FI52715C (fi) | 1977-11-10 |
| CH529742A (de) | 1972-10-31 |
| ES387834A1 (es) | 1973-06-01 |
| DK136311C (de) | 1978-02-20 |
| AT303274B (de) | 1972-11-27 |
| NL7018260A (de) | 1971-08-04 |
| CA963910A (en) | 1975-03-04 |
| IL35987A (en) | 1974-01-14 |
| YU34355B (en) | 1979-07-10 |
| DK136311B (da) | 1977-09-26 |
| IE35133B1 (en) | 1975-11-26 |
| DE2102586A1 (de) | 1971-08-12 |
| DE2102586C2 (de) | 1985-03-14 |
| SE373133B (de) | 1975-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jenkins et al. | Inhibition of adrenal steroid 11-oxygenation in the dog | |
| CA1142092A (en) | Method of preventing carcinogenesis | |
| AU2011344030B2 (en) | 3-methanesulfonylpropionitrile for treating inflammation and pain | |
| EP1736167B1 (de) | Extrakten aus Zellinien von Syringa vulgaris IRB-SV25/B (DMS:16857), ihre Vorbereitung und Verwendung davon | |
| JPH03170499A (ja) | ドラスタチン１４ | |
| AU688029B2 (en) | An equilin double bond isomer from the acid isomerization of equilin | |
| US20030032617A1 (en) | Composition and methods for the treatment of skin disorders | |
| JPS61260091A (ja) | 新規なエリスロマイシンａ・脂肪酸エステル、それらの製法及びそれらを含有している医薬及び化粧料組成物 | |
| KR850000065B1 (ko) | 린코마이신 및 클린다마이신의 제조방법 | |
| Zheng et al. | Inhibition of the autoxidation of linoleic acid by phenylpropanoid glycosides from Pedicularis in micelles | |
| EP0010668B1 (de) | 3-Deazaadenosine und sie enthaltende pharmazeutische Zusammensetzungen | |
| Thompson et al. | Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans-retinamide in rats and mice | |
| JP2504990B2 (ja) | 新規な抗生物質レチノイン酸エステル、その製造法並びにそれを含有する皮膚病治療用組成物及び化粧料組成物 | |
| Hirschberg et al. | Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl) aminomethyl] benzimidazole, and of other 2-chloroethyl compounds | |
| US5061723A (en) | Non-teratogenic vitamin A preparation for women of child-bearing age | |
| JPS6236395A (ja) | プソイドプテロシンの合成誘導体、及びそれを含む剤 | |
| EP0038567B1 (de) | Deazapurin-Nukleosid, es enthaltende Zusammensetzungen und seine therapeutische Verwendung | |
| US3755604A (en) | Sebum inhibitors | |
| US3170923A (en) | 17-tetrahydropyranylethers of delta4, 6-androstadienes | |
| DE2102586A1 (de) | Saureamide | |
| JPH07179418A (ja) | ビタミンｄ３−類似体 | |
| EP0983063B1 (de) | Pharmazeutische zusammensetzung enthaltend uscharin | |
| US3574853A (en) | Composition and method of reducing serum cholesterol with thiobiscresols | |
| EP0194710A2 (de) | Fruktose-Derivat, seine Herstellung und Verwendung | |
| KORNBLEE et al. | GAMMEXANE® IN TREATMENT OF SCABIES |